Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions (DERMOCOS)

Cancer treatments can trigger cutaneous side-effects, as well as nail and hair toxicities. When related to drug treatment, this iatrogeny depends on the type of drug, its dosage and individual susceptibility. Although these dermatological adverse events are rarely serious, they can significantly alter patients' quality of life, and may even necessitate the introduction of curative treatment.

The impact of these side effects can be mitigated by the use of dermo-cosmetic products and aesthetic solutions. However, most of this supportive care is not reimbursed by the health insurance system, representing a source of inequalities in access to healthcare for cancer patients.

Study Overview

• Status: Recruiting
• Conditions: Neoplasms
• Intervention / Treatment: Other: Questionnaires

Detailed Description

This study aims at establishing, in a cohort of patients with solid tumors, the state of their knowledges, given information and their financial capacities regarding access to dermo-cosmetics and aesthetic solutions, that are used in the attenuation of cancer treatments' side-effects.

• Study Type: Observational
• Enrollment (Estimated): 210

Contacts and Locations

• Study Contact: Name: Manon VOEGELIN; Phone Number: 33 (0)3 68 33 95 23; Email: promotion-rc@icans.eu
• Study Contact Backup: Name: Claire VIT; Phone Number: (0)3 88 25 85 29; Email: promotion-rc@icans.eu

Study Locations

• France
  • Strasbourg, France, 67033
    • Recruiting
    • Institut de cancérologie Strasbourg Europe
    • Contact: Nelly ETIENNE-SELLOUM, PharmD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

This study will enroll patients with solid tumors in 7 different cohorts according to tumor location (30 patients per location)

Description

Inclusion Criteria:

• Age > 18 years
• Patients with solid tumors (eligible localization include: digestive system, Head and Neck, Breast, Brain, Lung Tumors, Urological and Gynecologic cancers)
• Patients able to read and understand French
• Patients that has expressed their consent and with signed consent form

Exclusion Criteria:

• Minor or patients placed under guardianship or supervision
• Patients unable to read French
• Patients placed under judicial protection

Study Plan

How is the study designed?

Number of groups / cohorts

7

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients with Breast Cancer	Other: Questionnaires; 25-items questionnaire
Patients with Digestive System Cancer	Other: Questionnaires; 25-items questionnaire
Patients with Head and Neck Cancer	Other: Questionnaires; 25-items questionnaire
Patients with Nervous System Tumors	Other: Questionnaires; 25-items questionnaire
Patients with Urological Cancer	Other: Questionnaires; 25-items questionnaire
Patients with Lung Cancer	Other: Questionnaires; 25-items questionnaire
Patients with Gynecologic Cancer	Other: Questionnaires; 25-items questionnaire

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Describe patients' knowledges regarding cutaneous side-effects, nail and hair toxicities induced by anticancer drugs	4 items questionnaires	at inclusion
Describe patients' knowledges regarding dermo-cosmetics and aesthetic solutions that can attenuate cutaneous side-effects, nail and hair toxicities induced by anticancer drugs	10 items questionnaires	at inclusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Describe patients' socio-economic profile to assess equity regarding access to dermo-cosmetics and aesthetic solutions	11 items questionnaires	at inclusion
Correlate patients' knowledge level depending on tumoral location	Tumoral location as described in medical chart	at inclusion
Correlate patients' knowledge level depending on received treatment	Type of chemotherapy administered on the day of inclusion as described in medical chart	at inclusion
Correlate patients' knowledge level depending on treatment phase	Type of treatment phase (i.e. neoadjuvant, adjuvant, 1st or 2nd metastatic line) as described in medical chart	at inclusion

Collaborators and Investigators

• Sponsor: Institut de cancérologie Strasbourg Europe
• Investigators: Study Chair: Nelly ETIENNE-SELLOUM, PharmD, Institut de cancérologie Strasbourg Europe

Study record dates

Study Major Dates

• Study Start (Actual): July 25, 2023
• Primary Completion (Estimated): October 25, 2023
• Study Completion (Estimated): October 25, 2023

Study Registration Dates

• First Submitted: June 8, 2023
• First Submitted That Met QC Criteria: June 8, 2023
• First Posted (Actual): June 18, 2023

Study Record Updates

• Last Update Posted (Actual): August 22, 2023
• Last Update Submitted That Met QC Criteria: August 21, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: 2023-001 (University of Missouri); 2023-A00546-39 (Other Identifier: ID-RCB Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No